RxDoctor Payments DataLook up a doctor →

Richard Leggett, DO

Family Medicine · Victoria, TXNPI 1336162064

Payments from drug & device makers

$6,999,798in general payments, 2019–2025

Across 1,076 payments — averaging $6505.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$4M
  • Merck$2.5M
  • Pfizer$290K
  • AstraZeneca$54K
  • AbbVie$43K
  • Astrazeneca UK Limited$24K
  • plus $29K from 37 others

What the payments were for

  • Travel & lodging$7,71651%
  • Food & beverage$7,00447%
  • Education$2952%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,999,798 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$126,949
Medicare patients
441
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$136,953
OzempicSemaglutide60$77,661
FarxigaDapagliflozin Propanediol72$68,554
TrulicityDulaglutide23$41,362
JanuviaSitagliptin Phosphate26$33,855
MounjaroTirzepatide21$23,361
JardianceEmpagliflozin32$22,725
XareltoRivaroxaban19$18,411
Tresiba Flextouch U-200Insulin Degludec16$14,499
MyrbetriqMirabegron28$14,191
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$10,738
Repatha SureclickEvolocumab15$9,902
Repatha SyringeEvolocumab14$8,717
Breo ElliptaFluticasone/Vilanterol14$7,901
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$289,994$136,953139 claims
AstraZenecaFarxiga, Breztri Aerosphere$53,751$79,29387 claims
Novo NordiskOzempic$777$77,66160 claims
Lilly USA, LLCTrulicity, Mounjaro$231$64,72344 claims
MerckJanuvia$2,548,909$33,85526 claims
Boehringer IngelheimJardiance$69$22,72532 claims
Johnson & JohnsonXarelto$112$18,41119 claims
Astellas Pharma US IncMyrbetriq$358$14,19128 claims
GSKBreo Ellipta$185$7,90114 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$15$2,37211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Victoria

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →